Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 187

The DOI matches its Crossref record.

Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Trials of Adjuvant Epirubicin for Early Breast Cancer: Correlation With Doses of Epirubicin and Cyclophosphamide

Open access
Praga, Claudio, Bergh, Jonas, Bliss, Judith, Bonneterre, Jacques, Cesana, Bruno, Coombes, R. Charles, Fargeot, Pierre, Folin, Annika, Fumoleau, Pierre, Giuliani, Rosa, Kerbrat, Pierre, Hery, Michel, Nilsson, Jonas, Onida, Francesco, Piccart, Martine, Shepherd, Lois, Therasse, Patrick, Wils, Jacques, Rogers, David·2005·Journal of Clinical Oncology

Abstract

Purpose: We reviewed follow-up of patients treated in 19 randomized trials of adjuvant epirubicin in early breast cancer to determine incidence, risk, and risk factors for subsequent acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Patients and Methods: The patients (N = 9,796) were observed from the start of adjuvant treatment (53,080 patient-years). Cases of AML or MDS (AML/MDS) were reported, with disease characteristics. Incidence and cumulative risk were compared for possible risk factors, for assigned regimens, and for administered cumulative doses of epirubicin and cyclophosphamide. Results: In 7,110 patients treated with epirubicin-containing regimens (92% of whom also received cyclophosphamide), 8-year cumulative probability of AML/MDS was 0.55% (95% CI, 0.33% to 0.78%). The risk of developing AML/MDS increased in relation to planned epirubicin dose per cycle, planned epirubicin dose-intensity, and administered cumulative doses of epirubicin and cyclophosphamide. Patients with administered cumulative doses of both epirubicin and cyclophosphamide not exceeding those used in standard regimens (≤ 720 mg/m 2 and ≤ 6,300 mg/m 2, respectively) had an 8-year cumulative probability of developing AML/MDS of 0.37% (95% CI, 0.13% to 0.61%) compared with 4.97% (95% CI, 2.06% to 7.87%) for patients administered higher cumulative doses of both epirubicin and cyclophosphamide. Conclusion: Patients treated with standard cumulative doses of adjuvant epirubicin (≤ 720 mg/m 2) and cyclophosphamide (≤ 6,300 mg/m 2) for early breast cancer have a lower probability of secondary leukemia than patients treated with higher cumulative doses. Increased risk of secondary leukemia must be considered when assessing the potential benefit to risk ratio of higher than standard doses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2005.05.029

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 187

Metadata

Authors
Praga, C., Bergh, J., Bliss, J., Bonneterre, J., Cesana, B., Coombes, R. C., Fargeot, P., Folin, A., Fumoleau, P., Giuliani, R., Kerbrat, P., Hery, M., Nilsson, J., Onida, F., Piccart, M., Shepherd, L., Therasse, P., Wils, J., & Rogers, D.
Venue
Journal of Clinical Oncology
Published
2005-06-20
Volume
23
Issue
18
Pages
4179-4191
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2149708286
Cited by
187
References
0
FWCI
9.38
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Trials of Adjuvant Epirubicin for Early Breast Cancer: Correlation With Doses of Epirubicin and Cyclophosphamide. https://app.cochat.ai/papers/10.1200/jco.2005.05.029
The paper
Praga, C., Bergh, J., Bliss, J., Bonneterre, J., Cesana, B., Coombes, R. C., Fargeot, P., Folin, A., Fumoleau, P., Giuliani, R., Kerbrat, P., Hery, M., Nilsson, J., Onida, F., Piccart, M., Shepherd, L., Therasse, P., Wils, J., & Rogers, D. (2005). Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Trials of Adjuvant Epirubicin for Early Breast Cancer: Correlation With Doses of Epirubicin and Cyclophosphamide. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.05.029

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.